The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4461-4467

  Svatek, Robert S ^a,b   Shariat, Shahrokh F ^d   Lasky, Robert E ^b   Skinner, Eila C ^e   Novara, Giacomo ^f   Lerner, Seth P ^c   Fradet, Yves ^g   Bastian, Patrick J ^h   Kassouf, Wassim ⁱ   Karakiewicz, Pierre I ^j   Fritsche, Hans Martin ^k   Müller, Stefan C ^l   Izawa, Jonathan I ^m   Ficarra, Vincenzo ^f   Sagalowsky, Arthur I ^d   Schoenberg, Mark P ⁿ   Siefker Radtke, Arlene O ^a   Millikan, Randall E ^a   Dinney, Colin P N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITÉ LAVAL   (Canada)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k UNIVERSITY OF REGENSBURG   (Germany)

^l UNIVERSITY OF BONN   (Germany)

^m UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; COXSACKIE VIRUS; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 77956244798     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0457     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55: 815-25.
3. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-6.
4. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
5. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-22, discussion 22.
6. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005;2:CD005246, DOI: 10.1002/14651858.CD005246.
7. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561-9.
8. Ruggeri EM, Giannarelli D, Bria E, et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer 2006;106:783-8.
9. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155:495-9, discussion 9-500.
10. Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994;152:81-4.
11. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC): an Italian multicenter randomised phase III trial. J Clin Oncol 2008;26:15S, (abstr 5023).
12. Otto T, Goebell PJ, Rubben H. Perioperative chemotherapy in advanced bladder cancer - part II: adjuvant treatment. Onkologie 2003;26:484-8.
13. Logothetis CJ, Johnson DE, Chong C, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988;6:1590-6.
14. Bria E, Ruggeri EM, Pollera CF, Terzoli E, Cognetti F, Giannarelli D. Adjuvant chemotherapy for bladder cancer: the chance for metaanalyses comparison. Eur Urol 2007;51:576-7.
15. Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52.
16. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189-99, discussion 99-201.
17. Berlowitz DR, Brandeis GH, Moskowitz MA. Using administrative databases to evaluate long-term care. J Am Geriatr Soc 1997;45:618-23.
18. Markman M. Use of systemic antineoplastic drug therapy after regulatory agency approval. Oncology 2007;72:145-6.
19. Stadler WM, Lerner SP, Groshen S, et al. Randomized trial of p53 targeted adjuvant therapy for patients with organ confined node negative urothelial bladder cancer. J Clin Oncol 2009;27:15S, (abstr. 5017).
20. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2008;2009;55: 348-58.
21. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000;11:851-6.
22. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
23. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
24. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
25. Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008;112:2384-92.